Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mycobacteria-specific CD4+ T cells are a specialized population of T helper lymphocytes that play a critical role in the host defense against Mycobacterium tuberculosis (Mtb) and other mycobacterial pathogens. These cells recognize mycobacterial peptides presented by Major Histocompatibility Complex (MHC) class II molecules on the surface of antigen-presenting cells, such as macrophages and dendritic cells (Jasenosky et al., 2015, Nature Reviews Immunology). Upon activation, they differentiate primarily into Th1 and Th17 subsets, secreting essential cytokines like interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) which are vital for activating macrophages to restrict intracellular bacterial growth (O'Garra et al., 2013, Journal of Experimental Medicine). They are also instrumental in the formation and maintenance of granulomas, the organized cellular structures that sequester Mtb during latent infection. In clinical medicine, the presence and activity of these cells are monitored via Interferon-Gamma Release Assays (IGRAs) to diagnose infection (CDC, 2019). Therapeutic strategies, particularly vaccines like BCG and novel candidates (e.g., MTBVAC), aim to elicit robust and long-lasting mycobacteria-specific CD4+ T cell memory to prevent active disease. Conversely, the loss of these cells, most notably in HIV-infected individuals, leads to a profound susceptibility to tuberculosis, highlighting their indispensable role in protective immunity.
Vaccines and immunotherapies target these cells to induce or enhance an antigen-specific immune response, primarily through the presentation of mycobacterial antigens by MHC class II molecules, leading to T-cell proliferation and the secretion of protective cytokines like IFN-gamma and TNF-alpha (Jasenosky et al., 2015, Nature Reviews Immunology).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycobacteria-specific CD4+ T cells (Mtb-specific CD4+ T cells).